Immune checkpoint inhibitor-induced myocarditis and outcomes after re-exposure
- real-world study
Authors' conclusion
ICI-induced myocarditis increases mortality, while re-exposure may improve survival in selected patients.
Study context
- Population
- Adult patients with cancer treated with immune checkpoint inhibitors (ICIs), identified from TriNetX networkpatients receiving ICIs, 1,214 developed myocarditis, of whom 168 were re-exposed to ICIs
- Participants
- 195,578 patients
- Comparison
- outcomes were compared between patients re-exposed to ICI and those who were not
- re-exposed to ICIn = 168
Main finding
As reported in the abstract
Incidence of ICI-induced myocarditis
developed myocarditis, of 195,578 patients receiving ICIs
0.6% (n=1,214)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality, myocarditis vs no myocarditis · increased all-cause mortality with myocarditis | 1.44 (1.25–1.66) | |
| All-cause mortality after re-exposure, among those with myocarditis · lower all-cause mortality with re-exposure | 0.50 (0.35–0.73) | |
| 0.20.5125Hazard ratio (log scale) |
- All-cause mortality after re-exposure, among those with myocarditis: Among those with myocarditis, 13.8% (n=168) were re-exposed to ICIs
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Immune checkpoint inhibitor-induced myocarditis and outcomes after re-exposure. Am Heart J. Published 2 April 2026. doi:10.1016/j.ahj.2026.107438
Summarised from the published abstract; every number is checked against it